- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Error threshold.
Displaying page 1 of 1.
| EudraCT Number: 2021-003242-20 | Sponsor Protocol Number: p135 | Start Date*: 2023-03-09 |
| Sponsor Name:Maastricht University | ||
| Full Title: Effects of recreational nitrous oxide use on psychomotor functioning related to driving performance | ||
| Medical condition: The impairing effects of recreational nitrous oxide use on psychomotor functioning related to driving performance and its relation to detected concentration in exhaled air | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-005270-10 | Sponsor Protocol Number: NALISO-II-20-1 | Start Date*: 2021-08-18 | |||||||||||
| Sponsor Name:LABORATOIRES SMB S.A | |||||||||||||
| Full Title: A randomized, partially blinded, parallel study to evaluate the effects of nacystelyn in combination with isotretinoin in the treatment of recalcitrant acne vulgaris. | |||||||||||||
| Medical condition: Recalcitrant acne vulgaris | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-003079-31 | Sponsor Protocol Number: QRK207 | Start Date*: 2016-10-20 | |||||||||||
| Sponsor Name:Quark Pharmaceuticals Inc. | |||||||||||||
| Full Title: A PHASE 2/3, RANDOMIZED, DOUBLE-MASKED, SHAMCONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTION(S) TO SUBJECTS WITH ACUTE NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEU... | |||||||||||||
| Medical condition: NAION typically presents as an abrupt, painless monocular vision loss. Visual loss varies widely, ranging from visual field loss only to complete blindness. The neuronal degeneration process in N... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-002204-27 | Sponsor Protocol Number: GS030_CLIN_001 | Start Date*: 2017-12-22 |
| Sponsor Name:GENSIGHT-BIOLOGICS | ||
| Full Title: A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects with Retinitis Pigmentosa | ||
| Medical condition: Retinitis Pigmentosa | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-000311-25 | Sponsor Protocol Number: BAY86-9766/16553 | Start Date*: 2013-10-17 |
| Sponsor Name:Bayer Healthcare AG | ||
| Full Title: A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma (HCC) | ||
| Medical condition: KRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CZ (Completed) BE (Completed) AT (Completed) GB (Completed) DE (Completed) HU (Completed) ES (Completed) IT (Completed) FR (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2013-000241-39 | Sponsor Protocol Number: BAY86-9766/16728 | Start Date*: 2013-07-26 |
| Sponsor Name:Bayer HealthCare AG | ||
| Full Title: A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in combination with sorafenib as first line treatment in patients with RAS mutant Hepato... | ||
| Medical condition: KRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) CZ (Completed) GB (Completed) DE (Completed) BE (Completed) IT (Completed) HU (Completed) ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-004363-21 | Sponsor Protocol Number: 1042-0603 | Start Date*: 2015-03-11 | |||||||||||
| Sponsor Name:Marinus Pharmaceuticals, Inc | |||||||||||||
| Full Title: A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults with Drug-Resistant Partial-Onset Seizures Foll... | |||||||||||||
| Medical condition: Drug-Resistant Epilepsy with Partial-Onset Seizures | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
